CLDN5

Claudin-5

Score: 0.450 Price: $0.45 Undruggable Druggability Status: active Wiki: CLDN5

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

152

DEBATES

3D Protein Structure

🧬 CLDN5 — PDB 6OV2 Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Undruggable

Score: 0.20

Clinical Stage

Approved

Target Class

Structural Protein

Safety

0.30

Druggability Analysis

Drug Development0.60

Structural Tractability0.30

Target Class0.50

Safety Profile0.30

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (2 compounds)

2 Preclinical

Druggability Rationale: Despite CLDN5's critical role in blood-brain barrier integrity and neurological disease pathogenesis, it remains a challenging druggability target due to limited established pharmacological intervention mechanisms. While preclinical anti-CLDN5 antibodies and size-selective BBB modulators show potential promise, the lack of clear structure-based drug design strategies and the protein's complex tight junction functional role currently constrains direct therapeutic targeting. Further structural and mechanistic research is needed to develop precise molecular strategies for modulating CLDN5's function in neurodegeneration.

Mechanism: Tight junction protein modulation - no established druggable mechanisms

Drug Pipeline (2 compounds)

2 Preclinical

Known Drugs:

Anti-CLDN5 antibodies (preclinical) — Transient BBB opening for drug delivery

Size-selective BBB modulators (preclinical) — Claudin-5 targeted siRNA for BBB modulation

Structural Data:

PDB —AlphaFold ✓Cryo-EM —

UniProt: O00501

🧬 3D Protein Structure

🧬 CLDN5 — PDB 6OV2 Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

Selectivity is a critical challenge given CLDN5's widespread expression across multiple claudin family members (CLDN1-24) and its tissue distribution beyond the BBB in other tight junction barriers. Off-target disruption of gastrointestinal, renal, or skin barrier function poses significant safety liabilities; any therapeutic approach requires BBB-specific targeting strategies to minimize systemic claudin modulation.